ESR1 and breast carcinoma: To characterize the role of APOC1P1-3 overexpression in breast cancers, we examined the relationship between expression of APOC1P1-3 and clinicopathologic parameters (age, molecular subtypes (luminal A like, luminal B like, HER2 positive, and triple negative),7 breast cancer biomarkers (estrogen receptor (ER), progesterone receptor (PgR), and HER2), lymph node status, distant metastasis, and pTNM stage).